| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
13,630,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile INmune Bio is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Co. has two product platforms: dominant negative tumor necrosis factor, which is being developed for Alzheimer's and treatment resistant depression (XPro) and cancer (INB03); and Natural Killer Cell Priming Platform, which utilizes a precision medicine approach for the treatment of a variety of hematologic malignancies, solid tumors and chronic inflammation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
80,082 |
87,082 |
87,082 |
106,582 |
| Total Buy Value |
$666,282 |
$714,932 |
$714,932 |
$840,027 |
| Total People Bought |
4 |
4 |
4 |
4 |
| Total Buy Transactions |
4 |
5 |
5 |
9 |
| Total Shares Sold |
0 |
0 |
10,000 |
10,000 |
| Total Sell Value |
$0 |
$0 |
$110,085 |
$110,085 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tesi Raymond Joseph |
President and CEO |
• • • |
2024-04-19 |
4/A |
B |
$8.32 |
$149,993 |
D/D |
18,028 |
1,538,726 |
3.23 |
- |
|
| Moss David J |
CFO, Treasurer & Secretary |
• – • |
2024-04-19 |
4/A |
B |
$8.32 |
$149,993 |
D/D |
18,028 |
1,268,179 |
4.01 |
- |
|
| Lowdell Mark William |
Chief Scientific Officer |
• – • |
2024-04-19 |
4/A |
B |
$8.32 |
$119,999 |
D/D |
14,423 |
1,510,806 |
4.01 |
- |
|
| Juda Scott |
Director |
– • – |
2024-04-19 |
4/A |
B |
$8.32 |
$246,297 |
D/D |
29,603 |
66,603 |
2.39 |
- |
|
| Juda Scott |
Director |
– • – |
2024-04-19 |
4 |
A |
$8.32 |
$246,297 |
D/D |
29,603 |
66,603 |
|
- |
|
| Lowdell Mark William |
Chief Scientific Officer |
• – • |
2024-04-19 |
4 |
A |
$8.32 |
$119,999 |
D/D |
14,423 |
1,510,806 |
|
- |
|
| Tesi Raymond Joseph |
President and CEO |
• • • |
2024-04-19 |
4 |
A |
$8.32 |
$149,993 |
D/D |
18,028 |
1,538,726 |
|
- |
|
| Moss David J |
CFO, Treasurer & Secretary |
• – • |
2024-04-19 |
4 |
A |
$8.32 |
$149,993 |
D/D |
18,028 |
1,268,179 |
|
- |
|
| Juda Scott |
Director |
– • – |
2023-11-10 |
4 |
B |
$6.95 |
$48,650 |
I/I |
7,000 |
37,000 |
2.1 |
- |
|
| Schroeder Timothy J |
Director |
– • – |
2023-07-12 |
4 |
AS |
$11.01 |
$110,085 |
I/I |
(10,000) |
82,187 |
|
- |
|
| Moss David J |
CFO, Treasurer & Secretary |
• – • |
2023-03-17 |
4 |
B |
$6.43 |
$16,063 |
D/D |
2,500 |
1,250,151 |
4.01 |
- |
|
| Moss David J |
CFO, Treasurer & Secretary |
• – • |
2022-05-27 |
4 |
B |
$6.79 |
$20,370 |
D/D |
3,000 |
1,247,651 |
4.01 |
- |
|
| Tesi Raymond Joseph |
President and CEO |
• • • |
2022-05-26 |
4 |
B |
$6.41 |
$40,383 |
D/D |
6,300 |
1,520,698 |
3.23 |
- |
|
| Moss David J |
CFO, Treasurer & Secretary |
• – • |
2022-05-26 |
4 |
B |
$6.27 |
$48,279 |
D/D |
7,700 |
1,244,651 |
4.01 |
- |
|
| Moss David J |
CFO, Treasurer & Secretary |
• – • |
2022-03-22 |
4 |
A |
$8.43 |
$149,995 |
D/D |
17,793 |
1,236,951 |
|
- |
|
| Ganjei James Kelly |
Director |
– • – |
2022-03-22 |
4 |
A |
$8.43 |
$149,995 |
D/D |
17,793 |
17,793 |
|
- |
|
| Tesi Raymond Joseph |
President and CEO |
• • • |
2022-03-22 |
4 |
A |
$8.43 |
$199,993 |
D/D |
23,724 |
1,514,398 |
|
- |
|
| Lowdell Mark William |
Chief Scientific Officer |
• – • |
2022-03-22 |
4 |
A |
$8.43 |
$198,864 |
D/D |
23,590 |
1,496,383 |
|
- |
|
| Juda Scott |
Director |
– • – |
2021-11-17 |
4 |
B |
$13.55 |
$33,875 |
I/I |
2,500 |
30,000 |
2.1 |
- |
|
| Tesi Raymond Joseph |
President and CEO |
• • • |
2021-11-03 |
4 |
AS |
$20.00 |
$72,520 |
D/D |
(3,626) |
1,490,674 |
|
- |
|
| Moss David J |
CFO, Treasurer & Secretary |
• – • |
2021-11-03 |
4 |
AS |
$20.00 |
$20,500 |
D/D |
(1,025) |
1,219,158 |
|
- |
|
| Lowdell Mark William |
Chief Scientific Officer |
• – • |
2021-11-03 |
4 |
AS |
$20.00 |
$14,020 |
D/D |
(701) |
1,472,793 |
|
- |
|
| Tesi Raymond Joseph |
President and CEO |
• • • |
2021-10-27 |
4 |
AS |
$20.00 |
$130,340 |
D/D |
(6,517) |
1,494,300 |
|
- |
|
| Lowdell Mark William |
Chief Scientific Officer |
• – • |
2021-10-27 |
4 |
AS |
$20.00 |
$47,140 |
D/D |
(2,357) |
1,473,494 |
|
- |
|
| Moss David J |
CFO, Treasurer & Secretary |
• – • |
2021-10-27 |
4 |
AS |
$20.00 |
$41,580 |
D/D |
(2,079) |
1,220,183 |
|
- |
|
65 Records found
|
|
Page 1 of 3 |
|
|
